HCP Resources - LODOCO

Q: What is LODOCO® indicated for?

LODOCO ® is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic cardiovascular disease or with multiple risk factors. Please refer to the Full Prescribing Information for full details.

Q: How is LODOCO® different from 0.6mg colchicine?

LODOCO ® is the only colchicine product FDA-approved at a 0.5 mg dose specifically to reduce cardiovascular risk. In contrast, other colchicine products—typically dosed at 0.6 mg—are indicated for conditions like gout and pericarditis, not for long-term cardiovascular prevention. Because colchicine is a narrow therapeutic index (NTI) drug, even small dose differences can lead to disproportionate toxicity. Prescribing a 0.6 mg tablet instead of LODOCO ® results in a 20% overdose every day, which may significantly increase the risk of adverse effects — especially in older adults or those with renal or hepatic impairment, who are common in the CVD population. Higher doses are associated with: Increased risk of gastrointestinal intolerance (e.g., diarrhea, nausea) Greater likelihood of treatment discontinuation Elevated risk of serious toxicity, including neuromyopathy and cytopenias, particularly in patients with compromised clearance Additionally: LODOCO ® ’s dose and indication are supported by cardiovascular outcomes trials, which are not applicable to 0.6 mg colchicine. Labeling substitution with 0.6 mg colchicine undermines evidence-based care and may expose patients to unnecessary harm. For appropriate use, LODOCO ® should be prescribed specifically, with “Do Not Substitute” selected in your EHR. See Full Prescribing Information for full safety and dosing details.

Q: Can I e-prescribe LODOCO®?

Yes, LODOCO ® is available in all major e-prescribing platforms. To ensure accurate dispensing, select: Drug Name: LODOCO ® (colchicine 0.5 mg) tablets NDC: 82867-001-01 Quantity: As directed (commonly 90 tablets for a 90-day supply) Directions: Once daily

LODOCO^® is the first and only FDA-approved anti-inflammatory to reduce cardiovascular risk.

This page provides prescribing tools, access support, and resources to help you evaluate and support appropriate patients.

Why Choose LODOCO^®?

LODOCO^® is FDA-approved to reduce the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in adults with established heart disease or multiple risk factors.

Unlike other colchicine products (often used for gout at a 0.6 mg dose), LODOCO^® is uniquely formulated at a lower 0.5 mg dose, specifically for long-term cardiovascular care.

Taken once daily, LODOCO^® provides targeted risk reduction in a convenient tablet — and may help patients maintain cardiovascular stability over time.

Legal Disclaimer: You are now leaving the LODOCO website. This link will take you to an educational site that is not intended to promote any specific product.

HCP Booklet

This quick-reference guide equips you with key clinical data, patient selection tips, and prescribing logistics for LODOCO^® – helping you translate anti-inflammatory cardiology into everyday practice.

Request Samples

Order LODOCO^® samples for your eligible patients. Samples are provided at no cost to licensed healthcare providers.

Samples are available only to licensed HCPs and subject to availability. Not for resale.

Patient Access & Coverage

Help your patients access LODOCO^® through pharmacy partners and affordability programs.

Commercial Insurance

Eligible patients with commercial insurance may pay as little as $30 for a 90-day supply.*

*Eligibility criteria and restrictions apply. See offer terms for details.

Cash-Pay Option

Patients without insurance may qualify for a $99/month cash price through BlinkRx or Marley with free home delivery.

Patient Assistance Program (PAP)

Patients who meet income and insurance eligibility criteria may receive LODOCO^® at no cost.

Insurance Appeals Support

If a LODOCO^® prescription is initially rejected by insurance, an appeal can make all the difference.
Up to 98% of prescriptions are approved on appeal,
depending on the plan — don’t miss the chance to get your patient covered.

For assistance completing the form or submitting an appeal, contact our reimbursement support
team at 1-8888-AGEPHA (888-824-3742)

Frequently Asked Questions (FAQs)

What is LODOCO^® indicated for?

LODOCO^® is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic cardiovascular disease or with multiple risk factors.

Please refer to the Full Prescribing Information for full details.

How is LODOCO^® different from 0.6mg colchicine?

LODOCO^® is the only colchicine product FDA-approved at a 0.5 mg dose specifically to reduce cardiovascular risk. In contrast, other colchicine products—typically dosed at 0.6 mg—are indicated for conditions like gout and pericarditis, not for long-term cardiovascular prevention.

Because colchicine is a narrow therapeutic index (NTI) drug, even small dose differences can lead to disproportionate toxicity. Prescribing a 0.6 mg tablet instead of LODOCO^® results in a 20% overdose every day, which may significantly increase the risk of adverse effects — especially in older adults or those with renal or hepatic impairment, who are common in the CVD population.

Higher doses are associated with:

Increased risk of gastrointestinal intolerance (e.g., diarrhea, nausea)
Greater likelihood of treatment discontinuation
Elevated risk of serious toxicity, including neuromyopathy and cytopenias, particularly in patients with compromised clearance

Additionally:

LODOCO^®’s dose and indication are supported by cardiovascular outcomes trials,
which are not applicable to 0.6 mg colchicine.
Labeling substitution with 0.6 mg colchicine undermines evidence-based care and may
expose patients to unnecessary harm.

For appropriate use, LODOCO^® should be prescribed specifically, with “Do Not Substitute” selected in your EHR.
See Full Prescribing Information for full safety and dosing details.

How do I prevent substitution at the pharmacy?

Use “Do Not Substitute” when e-prescribing. You may also specify a digital pharmacy like BlinkRx or Marley to ensure the prescription is filled as intended.

Can I e-prescribe LODOCO^®?

Yes, LODOCO^® is available in all major e-prescribing platforms. To ensure accurate dispensing, select:

Drug Name: LODOCO^® (colchicine 0.5 mg) tablets
NDC: 82867-001-01
Quantity: As directed (commonly 90 tablets for a 90-day supply)
Directions: Once daily

Full Prescribing Information

Review the complete prescribing information, including indications, dosing, contraindications, and safety data.

Why Choose LODOCO®?